|  | Patients (N = 228) |
---|---|---|
Age (y/o) | (Median = 69) |  |
 | Age ≤ 60 | 11.0% |
 | 60 < Ages ≤ 70 | 45.6% |
 | Age > 70 | 43.4% |
Race | Â | Â |
 | White | 58.8% |
 | Black | 35.5% |
 | Other | 5.7% |
Partner status | Â | Â |
 | Yes | 75.40% |
 | No | 24.60% |
Employment status | Â | Â |
 | Yes | 47.40% |
 | No | 52.60% |
Median pre-treatment PSA (ng/mL) | Â | 6.1 (1.3-32.5) ng/dL |
Median pre-treatment Testosterone (nmol/L) | Â | 11 (3.99-39.87) nmol/L |
Risk groups (D’Amico’s) |  |  |
 | Low risk | 38.6% |
 | Intermediate risk | 55.3% |
 | High risk | 6.1% |
Sexual aid | Â | Â |
 | None | 61.9% |
 | Yes (Any) | 38.1% |
SBRT dose | Â | Â |
 | 36.25 Gy | 84.2% |
 | 35 Gy | 13.2% |
 | Other | 2.6% |